Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis
NCT: NCT07499791 · NOT_YET_RECRUITING
Brief Summary
This study aims to evaluate the safety and effectiveness of an absorbable lacrimal sac drug-eluting stent placed at the osteotomy site during endoscopic endonasal dacryocystorhinostomy (E-DCR) in patients with recurrent chronic dacryocystitis. The stent is composed of absorbable polymer mesh coated with mometasone furoate to reduce postoperative inflammation and adhesion, maintain ostium patency, and improve surgical outcomes. A total of 40 patients will be randomized 1:1 to receive either the absorbable stent or conventional packing with routine postoperative intranasal budesonide therapy.
Frequently Asked Questions
What is Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis?
Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis is a clinical trial registered under NCT07499791. Current status: NOT_YET_RECRUITING.
What is the status of NCT07499791?
The current status of NCT07499791 (Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis) is: NOT_YET_RECRUITING.
When did Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis start?
Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis started on 2026-05-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.